AMAG Pharmaceuticals Announces FDA Approval of Vyleesi™ (Bremelanotide Injection) for Acquired, Generalized Hypoactive Sexual Desire Disorder (HSDD) in Premenopausal Women

June 21, 2019

We're not around right now. But you can send us an email and we'll get back to you, asap.

Start typing and press Enter to search